Zydus Lifesciences Ltd Financials
Company Logo

Zydus Lifesciences Ltd Financial Statement

Zydus Lifesciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue4266.80
Operating Expense1787.30
Net Profit1700.80
Net Profit Margin39.86
Earning Per Share16.90
EBIDTA2478.40
Effective Tax Rate21.44

Zydus Lifesciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual10,818.70
Operating Expenses Annual6,760
Operating Profit Annual5,134.90
Interest Annual390.70
Depreciation504.40
Net Profit Annual3,441.50
Tax Annual798.30

Zydus Lifesciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning240.40
Cash Flow from Operations1,999.10
Cash Flow from Investing-1,830.60
Cash Flow from Financing-300.80
Cash Flow at the End108.10

Zydus Lifesciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)47.46
PBIT Margin (%)42.80
PBT Margin (%)42.69
Net PROFIT Margin (%)31.81
Return On Networth / Equity (%)23.45
Return On Networth /Employed (%)22.73
Return On Assets (%)16.86
Total Debt / Equity (X)0.37
Asset Turnover Ratio (%)0.53

Zydus Lifesciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual4,376.60
Total Current Assets Annual7,911.30
Non Current Assets Annual16,149
Total Shareholders Funds Annual15,716.50
Total Assets Annual24,084.80

Zydus Lifesciences Ltd Earning Calls

EPS (INR)

Expected

14.11

Reported

14.11

Surprise

0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by -0.51%

Sep 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 5, 2024, Zydus Lifesciences Ltd has a market capitalization of 1,01,151.67 Cr. Value Research classifies it as a Large-Cap company.
Yes, Zydus Lifesciences Ltd is debt-free with a debt-to-equity ratio of 0.39.
In FY 2023 , Zydus Lifesciences Ltd recorded a total revenue of approximately 10,317.60 Cr marking a significant milestone in the company's financial performance.
Zydus Lifesciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.5% and 0.2% annually, respectively..
Zydus Lifesciences Ltd's current PE ratio is 29.39.
Zydus Lifesciences Ltd's ROCE averaged 15.0% from the FY ending March 2022 to 2024, with a median of 13.6%. It peaked at 21.1% in March 2024, reflecting strong capital efficiency over the period..
Zydus Lifesciences Ltd's latest EBIT is Rs. 4,630.50 Cr, surpassing the average EBIT of Rs. 2,746.57 Cr over the 5 years..